Cancer remains one of the biggest health challenges of our lifetime.¹ Despite significant progress, it is the second leading cause of death worldwide, with nearly one in two people in the UK receiving a diagnosis of cancer within their lifetime.² 

Utilising its science and scale, Pfizer remains committed to tackling cancers. Our extensive portfolio and pipeline includes agents with mechanisms of action to attack cancer from different angles. And, with the addition of Seagen, a developer of antibody-drug conjugates (ADCs), we’re striving to be at the forefront of cancer care. 

Our focus areas include: breast cancers; genitourinary cancers, with prostate and bladder cancer; haematological cancers, with multiple myeloma and leukaemias; and thoracic cancers, which includes lung cancer.

Our broad and deep clinical development programs have the potential to reach new and larger patient populations, including new cancer types or expanded indications for already approved medicines in earlier lines of therapy.³ 

As of May 2024, Pfizer Oncology has 54 programs in development, including:³

• 26 new molecular entities
• 25 Phase 1 trials
• 9 Phase 2 trials
• 20 Phase 3 trials 

We are using our deep technical expertise to develop next-generation cancer therapies that span three core modalities: small molecules, ADCs and immuno-oncology biologics. 

At Pfizer, we remain committed to accelerating the next generation of cancer treatments. Through our R&D efforts and scientific partnerships, we’re striving for a future where more people than ever survive a diagnosis of cancer. While cancer never rests, nor do we.

References